74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Celldex Therapeutics Inc
Closed
SectorHealthcare
33.82 1.5
Overview
Share price change
24h
Min
33.32
Max
34.23
Income | -14M -81M |
|---|---|
Sales | 75K 75K |
EPS | -1.22 |
Profit margin | -108,422.667 |
Employees | 198 |
EBITDA | -7.8M -81M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +63.52% upside |
Market Cap | 472M 2.1B |
|---|---|
Previous open | 32.32 |
Previous close | 33.82 |
News Sentiment
By Acuity
100%
0%
339 / 348 Healthcare
Celldex Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Peer Comparison
Price change
Celldex Therapeutics Inc Forecast
Price Target
By TipRanks
63.52% upside
12 Months Forecast
Average 54.5 USD 63.52%
High 90 USD
Low 24 USD
Based on 11 Wall Street analysts offering 12 month price targets forCelldex Therapeutics Inc - Dist in the last 3 months.
Financials
$
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Live chat